TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05314686

Intervention type: OTHER
Intervention: Five exercise sessions of forty-five minutes within the pulmonary rehabilitation centre and ten days of using a physical activity tracker.
Description: 1. Five exercise sessions of forty-five minutes within the centre on a cycle ergometer using a pulse oximetry device connected to the telerehabilitation system through Bluetooth. Data recorded in the internal memory of the pulse oximeter will be compared with those transmitted through the telerehabilitation system.~2. Ten days of use of a physical activity tracker connected to the telerehabilitation system. Self-reported daily step count by the participants (using a standardized data sheet) will be compared with the daily step count transmitted through the telerehabilitation system.

Intervention type: OTHER
Intervention: Telerehabilitation
Description: An eight-week program including:~* Endurance training on a cycle ergometer (performed independently with remote monitoring or through video conference, according to the participant's preference), three times per week. Training prescription is progressively adjusted using an automated algorithm (aimed to first increase the training duration and then workload intensity).~* Peripheral muscle strengthening using the app (the patient will be requested to reproduce different exercises after watching a video) or through video conference, three times per week (thirty minutes).~* Daily walking with automated coaching.~* Self management education (one to nine sessions according to each individual needs, scheduled through videoconference).~* A self evaluation of symptoms through daily or weekly questionnaires. Different types of alert will be triggered at the center according to remote monitoring: non-adherence, clinical issue during endurance exercise sessions and change in symptoms.
Study: NCT05225896

Intervention type: GENETIC
Intervention: Description of clinical characteristic and genetic tumors
Description: This is a non-interventional study involving clinical data and biological samples (DNA). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes. Additionally, patients will be informed about the present study.
Study: NCT06290453

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA 27- FLP1 gene expression
Description: From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: micro RNA 27- FLP1 gene expression
Description: From each participant, 2 mL of blood will be drawn and store at 25-degree C. The expression of miRNA-27 and FLP1 gene will be measured using real time PCR.~Relative expression values will be normalised to the housekeeping gene GAPDH. The comparative cycle threshold (Ct) approach will be used to measure the relative expression of miRNA 27 and FLP1 gene. Then, using the equation -ΔΔCT, the fold change of each gene will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: The Expanded Disability Status Scale (EDSS)
Description: The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level of someone's disability over time. The EDSS has a range from 0 to 10.~Zero points is normal neurological examination. 10 points shows the MS-related death cases. Patients with EDSS score up to 5 are fully ambulatory patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrophysiological assessment:
Description: Electromyography and nerve conduction velocity will be performed for all MS patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI examination MRI brain:
Description: will be done on all MS patients to detect the number, the site, and the enhancement of lesions
Study: NCT04880135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised stretching and strengthening exercise
Description: The structure of the supervised exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based stretching and strengthening exercise
Description: The structure of the home based exercise sessions was a warm- up, followed by strengthening and finally stretching. Strengthening exercises will consist of a simple fitness plan of overhead press, push, pull and squat to stand which consist of 4 sets of 15 repetitions while stretching exercises protocol will be duration will be 4 sets of 10 repetitions. The total duration of the protocol will be of 50 to 60 minutes which consists of 10 minutes of warm up, strengthening for 20 to 25 minutes and stretching exercises for 15 to 20 minutes.
Study: NCT04664179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 1A: 2 x 10^7 cells/m2
Description: 2 x 10\^7 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2A: 6 x 10^7 cells/m2
Description: 6 x 10\^7 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 2B: 6 x 10^7 cells/m2
Description: 6 x 10\^7 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 3B: 2 x 10^8 cells/m2
Description: 2 x 10\^8 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose Level 3A: 2 x 10^8 cells/m2
Description: 2 x 10\^8 cells/m2
Study: NCT05058547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWEPPE
Description: In the smartphone application SWEPPE the individual can create an action plan, perform daily registrations of health aspects, self-monitoring of health aspects and goals, have access to a library with evidence-based facts and a coach, and possibility to share information with the employer.
Study: NCT06236373

Intervention type: OTHER
Intervention: Focus Groups or Interviews
Description: Focus groups and qualitative interview will be conducted with patients, caregivers and stake-holders trying to identify unmet needs of cancer survivors after the acute treatment phase. Individual interviews (in presence or online) will be hold as alternative if it will not be possible (due to logistical or personal problems) to participate in a focus group or if the number of people who would have agreed to participate in that focus group is less than 3
Study: NCT05443633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized speech-language training
Description: Language treatment might include lexical, semantic, and interactive treatment. During treatment, patients may be trained to name words by attempting to self-cue lexical retrieval. The therapy moves incrementally through semantic cuing. The semantic treatment will be implemented using the methods described in (Edmonds et al., 2009, 2014).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard language intervention
Description: Participants will undergo standard speech-language naming therapy
Study: NCT06176222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRECEDEX INJ★ 2ML
Description: patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
Study: NCT05885958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time
Description: Patients will be given up to 30 minutes to void.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time
Description: Patients will be given up to 60 minutes to void.
Study: NCT05619263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disaster PrepWise-Caregiver
Description: The Disaster PrepWise (DPW) intervention consists of five interactive modules and two supplemental sections (special topics and resources on various types of disasters). The five modules are: (1) Complete a Personal \& Household Assessment, (2) Develop a Personal Emergency Network, (3) Develop Emergency Information \& Gather Important Documents, (4) Keep a 3-5 Day Supply of Medications \& Medical Supplies, and (5) Build an Emergency Supply Kit. Through an initial visit (IV1) and a follow-up phone conversation 4 weeks later (IV2), the interventionist will develop a personalized disaster management plan and provide it to the participant for sharing with family and friends. Eight weeks after the initial session, the interventionist will make a final follow-up call (IV3) to provide any additional assistance caregivers may need.
Study: NCT05568212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab concentrate for solution for infusion will be supplied in glass vials containing 500 mg durvalumab at a concentration of 50 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Olaparib tablets (100 mg and 150 mg strengths) supplied in high-density polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Description: Investigator's choice single-agent chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent chemotherapy
Description: Investigator's choice single-agent chemotherapy regimen
Study: NCT06479499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: Group A will undergo Pilates exercise training, scheduled three times weekly over an 8-week period, for elderly individuals with COPD the duration and time interval time for Pilates exercise can vary depending on their overall health, fitness level, and tolerance. It begins with warm-up with 10-15 minutes which may include gentle stretches and deep breathing Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The exercise sessions lasting around 10-15 minutes and then gradually progressing to 20-30 minutes as the participants become more comfortable and their endurance improves. Maintain proper breathing during exercise and gradually increase the intensity as the person becomes stronger. The rest interval will be 1-2 minutes between exercise and then gradually reducing it to 30 seconds or less. Pilates session ends with a cool-down which may involve stretching and relaxation with duration of about 5-10 minutes.
Study: NCT05612256

Intervention type: DIAGNOSTIC_TEST
Intervention: Saturation oxygenation pressure index (SOPI)
Description: SOPI is assessed non-invasively and calculated from standard monitoring parameters such as PEEP, fraction of inspired oxygen pressure (FiO2) and peripheral oxyhaemoglobin saturation (SpO2) (PEEP x FiO2 x 100) / SpO2). SOPI is used to provide information on ventilation to perfusion ratio dependent on PEEP level.
Study: NCT06479499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Group B will engage in Aerobic exercise plan, following the same frequency and duration as the Pilates exercise program-three sessions per week for 8 weeks, It begins with a warm-up of 5-10 minutes to prepare body for exercise it includes gentle movements, stretching, or a few minutes of low-intensity aerobic activity. It includes main exercise with moderate intensity like brisk walking or jogging with duration of 5-10 minutes and increase to 20-30 minutes as participants improves their endurance. The short interval begins with 1-2 minutes than gradually reducing it to 30 seconds or less as a person builds up stamina and fitness. The cool-down duration at end of exercise will be 5-10 minutes.
Study: NCT04734067

Intervention type: OTHER
Intervention: Immune checkpoint inhibitors(ICIs) therapy
Description: Patients with malignant tumors who first received ICIs
Study: NCT05844267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental led booster breaks
Description: Participants in this group will receive interventions in the form of active breaks, administered by professionals in the relevant field, such as Physical Education teachers, for a period of 12 weeks. The active breaks will comprise exercises of light-to-moderate intensity, based on the guidelines provided by the Chilean safety association (ACHS), with an average duration of 14-16 minutes per day from Monday to Friday. The exercise types and progression will be elaborated in our protocol and published as supplementary material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental unled computer-prompts
Description: Participants in this group will receive interventions in the form of active breaks, facilitated through an application called Ponte de pie por tu salud, proposed by the Chilean Ministry of Health. This off-line application will be configured to generate breaks every hour, lasting for 2 minutes per break, over the course of 8 hours. This ensures that an average of 14-16 minutes of active breaks are accumulated throughout the day. Our research team will install the application on the participants' work computers and collect data from these computers weekly. At the end of the intervention period, the application will be uninstalled if necessary.
Study: NCT06056661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WMR
Description: Participants will complete up to five sessions that will take 2 hours each. Sessions will take place in person. Participants will learn skills related to getting into and out of romantic relationships and identifying and pursuing goals for romantic relationships.
Study: NCT06341556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).
Study: NCT05982496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FES
Description: 16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FES
Description: 16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FES
Description: 16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FES
Description: 16-alpha-18F-fluoro-17-beta-estradiol(FES) is a radiolabeled form of estrogen binding to functionally active ER which will be used as radiotracer for the PET/MRI exam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI A
Description: An additional FES PET/MRI will be performed before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI B
Description: Two additional PET/MRI will be performed before and after induction ET.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI C
Description: Two additional PET/MRI will be performed before and after two cycles of neoadjuvant chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MRI D
Description: Two additional PET/MRI will be performed before and after two cycles of systemic therapy.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Translational analysis
Description: Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Translational analysis
Description: Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Translational analysis
Description: Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Translational analysis
Description: Selected cases of heterogeneous tumors on imaging will be also investigated on pathology, imaging, genomic and radiomic levels.
Study: NCT05852379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active taVNS
Description: Transcutaneous auricular vague nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham taVNS
Description: Scham transcutaneous auricular vague nerve stimulation
Study: NCT04990037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Administered intravenously
Study: NCT06531837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine(Continuous infusion)
Description: Continuous intravenous infusion of esketamine at a dose of 0.2 mg/(kg · h). Collect resting-state EEG data and NRS scores 40 minutes after administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil (Target-Controlled Infusion)
Description: The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (Single intravenous injection)
Description: Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Collect resting-state EEG data and NRS scores with the spinal cord stimulator both turned off and on.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: Collect resting-state EEG data and NRS scores.
Study: NCT05966584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab 30mg subcutaneously on day -1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant or AIs) and PI3K inhibition (alpelisib)
Description: SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)
Study: NCT06490497

Intervention type: OTHER
Intervention: Interview
Description: individual interviews semi-directive
Study: NCT06301074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10509
Description: In SAD, participants will be assigned to receive either HS-10509 or a matching placebo for a single administration. There are 5 predefined dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), initially starting at 10 mg for cohort 1.~In MAD, participants will assigned to receive HS-10509 or a matching placebo once daily for 28 days. There will be 3 dose cohorts (each cohort including 8 for HS-10509 and 2 for placebo), and the dose for each cohort is to be determined.
Study: NCT06587360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fertiShare intervention - sharing bad news eLearning course
Description: two-hour self-led eLearning course to support fertility staff in sharing bad news (SBN) with their patients~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 offers SPIKES-based step-by-step guidance to ease SBNs. Module 3 offers guidance to cope with common challenges FHPs face: sharing bad news remotely, managing anger and uncertainty, and using good news to lessen the impact of bad news.~Each module offers video content-based lessons, case studies that illustrate guidance and brief quizzes for self-reflection and assessment. Case studies show learners optimal and suboptimal approaches to SBN.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fertiShare control - basic communication skills eLearning course
Description: self-led eLearning course branded as fertiShare but designed to emulate the basic communication training healthcare providers receive as they undergo their professional degrees.~organised in three modules. Module 1 explores definitions of bad news, why it is challenging to FHPs and patients, and the benefits of training. Module 2 introduces the communication cycle and associated communication techniques. Module 3 offers guidance regarding other basic communication skills: empathic communication, non-verbal communication, active listening and remote consultations, and communicating the likelihood of positive or negative treatment outcomes.~Each module offers video content-based lessons, case studies, and brief quizzes. All teaching elements remain at the basic level (remembering and understanding instead of analysing and applying).